SML3342
Trofinetide Trifluoroacetate
≥95% (HPLC)
Synonym(s):
Gly-2–methylPro–Glu Trifluoroacetate, Gly-2MePro-Glu Trifluoroacetate, Glycyl-2-methyl-L-prolyl-L-Glutamic acid Trifluoroacetate, NNZ 2566 Trifluoroacetate, NNZ-2566 Trifluoroacetate
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
Biochem/physiol Actions
Trofinetide is a more enzymatically stable analogue of the N-terminal tripeptide of IGF-1(GPE) that exhibits potent neuroprotective effects in varies animal models of neurodegenerative diseases and traumatic brain injury. Trofinetide treatment provides clinically meaningful improvement in Rett syndrome (RTT) and Fragile X syndrome (FXS).
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
NNZ-2566: a Gly-Pro-Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke.
Journal of the neurological sciences, 278(1-2), 85-90 (2009-01-23)
The N-terminal cleavage product of human insulin-like growth factor-1 (IGF-1) in the brain is the tripeptide molecule Glypromate (Gly-Pro-Glu). Glypromate has demonstrated neuroprotective effects in numerous in vitro and in vivo models of brain injury and is in clinical trials
Neuromolecular medicine, 15(3), 504-514 (2013-06-15)
The tripeptide glycine-proline-glutamate analogue NNZ-2566 (Neuren Pharmaceuticals) demonstrates neuroprotective efficacy in models of traumatic brain injury. In penetrating ballistic-like brain injury (PBBI), it significantly decreases injury-induced upregulation of inflammatory cytokines including TNF-α, IFN-γ, and IL-6. However, the mechanism by which
Pediatric neurology, 110, 30-41 (2020-07-15)
We analyze the safety and tolerability of trofinetide and provide a preliminary evaluation of its efficacy in adolescent and adult males with fragile X syndrome. This study was an exploratory, phase 2, multicenter, double-blind, placebo-controlled, parallel group study of the
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service